<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39337303</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9814</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25189814</ELocationID><Abstract><AbstractText>There is a need to investigate novel strategies in order to create an effective, broadly protective vaccine for current and future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks. The currently available vaccines demonstrate compromised efficacy against emerging SARS-CoV-2 variants of concern (VOCs), short-lived immunity, and susceptibility to immune imprinting due to frequent boosting practices. In this study, we examined the specificity of cross-reactive IgG antibody responses in mRNA-vaccinated, AstraZeneca-vaccinated, and unvaccinated donors to identify potentially conserved, cross-reactive epitopes to target in order to create a broadly protective SARS-CoV-2 vaccine. Our study provides evidence for cross-reactive IgG antibodies specific to eight different spike (S) variants. Furthermore, the specificities of these cross-variant IgG antibody titers were associated to some extent with spike S<sub>1</sub>- and S<sub>2</sub>-subunit-derived epitopes P<sub>1</sub> and P<sub>2</sub>, respectively. In addition, nucleocapsid (N)- and membrane (M)-specific IgG antibody titers correlated with N- and M-derived epitopes conserved across beta-CoVs, P<sub>3-7</sub>. This study reveals conserved epitopes of viral antigens, targeted by natural and/or vaccine-induced human immunity, for future designs of next-generation COVID-19 vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Raj S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glover</LastName><ForeName>Quarshie</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herchen</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9421-0428</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4754-1050</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Babita</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1957-6371</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PJT165854, PS173314</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="Y">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="Y">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">conserved epitopes</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39337303</ArticleId><ArticleId IdType="pmc">PMC11432605</ArticleId><ArticleId IdType="doi">10.3390/ijms25189814</ArticleId><ArticleId IdType="pii">ijms25189814</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization COVID-19 Cases WHO COVID-19 Dashboard.  [(accessed on 23 June 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases?n=o.</Citation></Reference><Reference><Citation>Patel R.S., Agrawal B. Heterologous Immunity Induced by 1st Generation COVID-19 Vaccines and Its Role in Developing a Pan-Coronavirus Vaccine. Front. Immunol. 2022;13:952229. doi: 10.3389/fimmu.2022.952229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.952229</ArticleId><ArticleId IdType="pmc">PMC9420909</ArticleId><ArticleId IdType="pubmed">36045689</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaide M., Chocarro de Erauso L., Bocanegra A., Blanco E., Kochan G., Escors D. MRNA Vaccines against SARS-CoV-2: Advantages and Caveats. Int. J. Mol. Sci. 2023;24:5944. doi: 10.3390/ijms24065944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065944</ArticleId><ArticleId IdType="pmc">PMC10051235</ArticleId><ArticleId IdType="pubmed">36983017</ArticleId></ArticleIdList></Reference><Reference><Citation>Röltgen K., Nielsen S.C.A., Silva O., Younes S.F., Zaslavsky M., Costales C., Yang F., Wirz O.F., Solis D., Hoh R.A., et al. Immune Imprinting, Breadth of Variant Recognition, and Germinal Center Response in Human SARS-CoV-2 Infection and Vaccination. Cell. 2022;185:1025–1040.e14. doi: 10.1016/j.cell.2022.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.018</ArticleId><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston T.S., Li S.H., Painter M.M., Atkinson R.K., Douek N.R., Reeg D.B., Douek D.C., Wherry E.J., Hensley S.E. Immunological Imprinting Shapes the Specificity of Human Antibody Responses against SARS-CoV-2 Variants. Immunity. 2024;57:912–925.e4. doi: 10.1016/j.immuni.2024.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2024.02.017</ArticleId><ArticleId IdType="pubmed">38490198</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Bretones M., Fouchier R.A.M., Koopmans M.P.G., van Nierop G.P. Impact of Antigenic Evolution and Original Antigenic Sin on SARS-CoV-2 Immunity. J. Clin. Investig. 2023;133:e162192. doi: 10.1172/JCI162192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI162192</ArticleId><ArticleId IdType="pmc">PMC9797340</ArticleId><ArticleId IdType="pubmed">36594464</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal B. Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections. Front. Immunol. 2019;10:2631. doi: 10.3389/fimmu.2019.02631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02631</ArticleId><ArticleId IdType="pmc">PMC6856678</ArticleId><ArticleId IdType="pubmed">31781118</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., Alter G., Crotty S., Plotkin S.A. Correlates of Protection against SARS-CoV-2 Infection and COVID-19 Disease. Immunol. Rev. 2022;310:6–26. doi: 10.1111/imr.13091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13091</ArticleId><ArticleId IdType="pmc">PMC9348242</ArticleId><ArticleId IdType="pubmed">35661178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W. Cell Surface SARS-CoV-2 Nucleocapsid Protein Modulates Innate and Adaptive Immunity. Sci. Adv. 2022;8:eabp9770. doi: 10.1126/sciadv.abp9770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abp9770</ArticleId><ArticleId IdType="pmc">PMC9348789</ArticleId><ArticleId IdType="pubmed">35921414</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Shi Y., Li P., Li L., Yi Y., Ma Q., Cao C. Profile of Antibodies to the Nucleocapsid Protein of the Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus in Probable SARS Patients. Clin. Diagn. Lab. Immunol. 2004;11:227–228. doi: 10.1128/CDLI.11.1.227-228.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.11.1.227-228.2004</ArticleId><ArticleId IdType="pmc">PMC321358</ArticleId><ArticleId IdType="pubmed">14715574</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng B., Ming Y., Yang C. Regulatory B Cells: The Cutting Edge of Immune Tolerance in Kidney Transplantation Review-Article. Cell Death Dis. 2018;9:109. doi: 10.1038/s41419-017-0152-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0152-y</ArticleId><ArticleId IdType="pmc">PMC5833552</ArticleId><ArticleId IdType="pubmed">29371592</ArticleId></ArticleIdList></Reference><Reference><Citation>Heide J., Schulte S., Kohsar M., Brehm T.T., Herrmann M., Karsten H., Marget M., Peine S., Johansson A.M., Sette A., et al. Broadly Directed SARS-CoV-2-Specific CD4+ T Cell Response Includes Frequently Detected Peptide Specificities within the Membrane and Nucleoprotein in Patients with Acute and Resolved COVID-19. PLoS Pathog. 2021;17:e1009842. doi: 10.1371/journal.ppat.1009842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009842</ArticleId><ArticleId IdType="pmc">PMC8445433</ArticleId><ArticleId IdType="pubmed">34529740</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W.J., Zhao M., Liu K., Xu K., Wong G., Tan W., Gao G.F. T-Cell Immunity of SARS-CoV: Implications for Vaccine Development against MERS-CoV. Antiviral Res. 2017;137:82–92. doi: 10.1016/j.antiviral.2016.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.11.006</ArticleId><ArticleId IdType="pmc">PMC7113894</ArticleId><ArticleId IdType="pubmed">27840203</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H., Yang L., Wang L., Li J., Huang J., Lu Z.Q., Koup R.A., Bailer R.T., Wu C. you Long-Lived Memory T Lymphocyte Responses against SARS Coronavirus Nucleocapsid Protein in SARS-Recovered Patients. Virology. 2006;351:466–475. doi: 10.1016/j.virol.2006.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2006.03.036</ArticleId><ArticleId IdType="pmc">PMC7111820</ArticleId><ArticleId IdType="pubmed">16690096</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., et al. Broad and Strong Memory CD4+ and CD8+ T Cells Induced by SARS-CoV-2 in UK Convalescent Individuals Following COVID-19. Nat. Immunol. 2020;21:1336–1345. doi: 10.1038/s41590-020-0782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyers L.M., Gutiérrez A.H., Boyle C.M., Terry F., McGonnigal B.G., Salazar A., Princiotta M.F., Martin W.D., De Groot A.S., Moise L. Highly Conserved, Non-Human-like, and Cross-Reactive SARS-CoV-2 T Cell Epitopes for COVID-19 Vaccine Design and Validation. NPJ Vaccines. 2021;6:71. doi: 10.1038/s41541-021-00331-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00331-6</ArticleId><ArticleId IdType="pmc">PMC8119491</ArticleId><ArticleId IdType="pubmed">33986292</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashi Y., Jagrit V., Kumar S. Understanding the B and T Cell Epitopes of Spike Protein of Severe Acute Respiratory Syndrome Coronavirus-2: A Computational Way to Predict the Immunogens. Infect. Genet. Evol. 2020;84:104382. doi: 10.1016/j.meegid.2020.104382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104382</ArticleId><ArticleId IdType="pmc">PMC7251353</ArticleId><ArticleId IdType="pubmed">32473352</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Sidney J., Methot N., Yu E.D., Zhang Y., Dan J.M., Goodwin B., Rubiro P., Sutherland A., Wang E., et al. Impact of SARS-CoV-2 Variants on the Total CD4+ and CD8+ T Cell Reactivity in Infected or Vaccinated Individuals. Cell Rep. Med. 2021;2:100355. doi: 10.1016/j.xcrm.2021.100355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100355</ArticleId><ArticleId IdType="pmc">PMC8249675</ArticleId><ArticleId IdType="pubmed">34230917</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C.K., Wu H., Yan H., Ma S., Wang L., Zhang M., Tang X., Temperton N.J., Weiss R.A., Brenchley J.M., et al. T Cell Responses to Whole SARS Coronavirus in Humans. J. Immunol. 2008;181:5490–5500. doi: 10.4049/jimmunol.181.8.5490.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.8.5490</ArticleId><ArticleId IdType="pmc">PMC2683413</ArticleId><ArticleId IdType="pubmed">18832706</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Sidney J., Zhang Y., Scheuermann R.H., Peters B., Sette A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe. 2020;27:671–680.e2. doi: 10.1016/j.chom.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.03.002</ArticleId><ArticleId IdType="pmc">PMC7142693</ArticleId><ArticleId IdType="pubmed">32183941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Wen J., Li J., Yin J., Zhu Q., Wang H., Yang Y., Qin E., You B., Li W., et al. Assessment of Immunoreactive Synthetic Peptides from the Structural Proteins of Severe Acute Respiratory Syndrome Coronavirus. Clin. Chem. 2003;49:1989–1996. doi: 10.1373/clinchem.2003.023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2003.023184</ArticleId><ArticleId IdType="pmc">PMC7108193</ArticleId><ArticleId IdType="pubmed">14633869</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R.S., Agrawal B. Mucosal Immunization with Lipopeptides Derived from Conserved Regions of SARS-CoV-2 Antigens Induce Robust Cellular and Cross-Variant Humoral Immune Responses in Mice. Front. Immunol. 2023;14:1178523. doi: 10.3389/fimmu.2023.1178523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1178523</ArticleId><ArticleId IdType="pmc">PMC10272440</ArticleId><ArticleId IdType="pubmed">37334376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontopodis E., Pierros V., Stravopodis D.J., Tsangaris G.T. Prediction of SARS-CoV-2 Omicron Variant Immunogenicity, Immune Escape and Pathogenicity, through the Analysis of Spike Protein-Specific Core Unique Peptides. Vaccines. 2022;10:357. doi: 10.3390/vaccines10030357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030357</ArticleId><ArticleId IdType="pmc">PMC8955659</ArticleId><ArticleId IdType="pubmed">35334990</ArticleId></ArticleIdList></Reference><Reference><Citation>Szymczak A., Jędruchniewicz N., Torelli A., Kaczmarzyk-Radka A., Coluccio R., Kłak M., Konieczny A., Ferenc S., Witkiewicz W., Montomoli E., et al. Antibodies Specific to SARS-CoV-2 Proteins N, S and E in Covid-19 Patients in the Normal Population and in Historical Samples. J. Gen. Virol. 2021;102:001692. doi: 10.1099/jgv.0.001692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001692</ArticleId><ArticleId IdType="pmc">PMC8742988</ArticleId><ArticleId IdType="pubmed">34816794</ArticleId></ArticleIdList></Reference><Reference><Citation>Den Hartog G., Schepp R.M., Kuijer M., Geurtsvankessel C., Van Beek J., Rots N., Koopmans M.P.G., Van Der Klis F.R.M., Van Binnendijk R.S. SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. J. Infect. Dis. 2020;222:1452–1461. doi: 10.1093/infdis/jiaa479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa479</ArticleId><ArticleId IdType="pmc">PMC7454740</ArticleId><ArticleId IdType="pubmed">32766833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Q., Li Y., Hou H., Wang F., Ouyang Z.Q., Zhang Y., Lai D.Y., Banga Ndzouboukou J.L., Xu Z.W., Zhang B., et al. Antibody Dynamics to SARS-CoV-2 in Asymptomatic COVID-19 Infections. Allergy Eur. J. Allergy Clin. Immunol. 2021;76:551–561. doi: 10.1111/all.14622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14622</ArticleId><ArticleId IdType="pmc">PMC7675426</ArticleId><ArticleId IdType="pubmed">33040337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicaloni V., Costanti F., Pasqui A., Bianchini M., Niccolai N., Bongini P. A Bioinformatics Approach to Investigate Structural and Non-Structural Proteins in Human Coronaviruses. Front. Genet. 2022;13:891418. doi: 10.3389/fgene.2022.891418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.891418</ArticleId><ArticleId IdType="pmc">PMC9237418</ArticleId><ArticleId IdType="pubmed">35774504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Asghar A., Singh H.N., Faiq M.A., Kumar S., Narayan R.K., Kumar G., Dwivedi P., Sahni C., Jha R.K., et al. SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis. JMIR Bioinform. Biotechmol. 2023;4:e42700. doi: 10.2196/42700.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/42700</ArticleId><ArticleId IdType="pmc">PMC9843602</ArticleId><ArticleId IdType="pubmed">36688013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajini A.A., Alkayyal A.A., Mubaraki F.A. The Recombination Potential between SARS-CoV-2 and MERS-CoV from Cross-Species Spill-over Infections. J. Epidemiol. Glob. Health. 2021;11:155–159. doi: 10.2991/jegh.k.201105.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2991/jegh.k.201105.001</ArticleId><ArticleId IdType="pmc">PMC8242116</ArticleId><ArticleId IdType="pubmed">33605109</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamminen K., Salminen M., Blazevic V. Seroprevalence and SARS-CoV-2 Cross-Reactivity of Endemic Coronavirus OC43 and 229E Antibodies in Finnish Children and Adults. Clin. Immunol. 2021;229:108782. doi: 10.1016/j.clim.2021.108782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108782</ArticleId><ArticleId IdType="pmc">PMC8188772</ArticleId><ArticleId IdType="pubmed">34118402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Yu D., Han Y., Yan H., Chong H., Ren L., Wang J., Li T., He Y. Cross-Reactive Neutralization of SARS-CoV-2 by Serum Antibodies from Recovered SARS Patients and Immunized Animals. Sci. Adv. 2020;6:eabc9999. doi: 10.1126/sciadv.abc9999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc9999</ArticleId><ArticleId IdType="pmc">PMC7673700</ArticleId><ArticleId IdType="pubmed">33036961</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo C.P., Le Sage V., Bolton M.J., Eilola T., Jones J.E., Kormuth K.A., Nturibi E., Balmaseda A., Gordon A., Lakdawala S.S., et al. Original Antigenic Sin Priming of Influenza Virus Hemagglutinin Stalk Antibodies. Proc. Natl. Acad. Sci. USA. 2020;117:17221–17227. doi: 10.1073/pnas.1920321117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1920321117</ArticleId><ArticleId IdType="pmc">PMC7382271</ArticleId><ArticleId IdType="pubmed">32631992</ArticleId></ArticleIdList></Reference><Reference><Citation>Petráš M., Králová Lesná I. SARS-CoV-2 Vaccination in the Context of Original Antigenic Sin. Hum. Vaccin. Immunother. 2022;18:1949953. doi: 10.1080/21645515.2021.1949953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1949953</ArticleId><ArticleId IdType="pmc">PMC8290366</ArticleId><ArticleId IdType="pubmed">34242123</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici M.A., Addetia A., Seo A.J., Brown J., Sprouse K.R., Logue J., Clark E., Franko N., Chu H., Veesler D. Persistent Immune Imprinting after XBB.1.5 COVID Vaccination in Humans. bioRxiv. 2023 doi: 10.1101/2023.11.28.569129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.11.28.569129</ArticleId><ArticleId IdType="pubmed">38490197</ArticleId></ArticleIdList></Reference><Reference><Citation>Blankson J.N. Bivalent COVID-19 Vaccines: Can the Original Antigenic Sin Be Forgiven? J. Infect. Dis. 2023;227:1221–1223. doi: 10.1093/infdis/jiad073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad073</ArticleId><ArticleId IdType="pmc">PMC10411926</ArticleId><ArticleId IdType="pubmed">37016931</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandhane A., Tripathy C.S., Behera S.K. Peptide and Protein Drug Delivery Using Polysaccharides. Elsevier; Amsterdam, The Netherlands: 2023. Peptide and Protein in Vaccine Delivery.</Citation></Reference><Reference><Citation>Grobben M., Van Der Straten K., Brouwer P.J., Brinkkemper M., Maisonnasse P., Dereuddre-Bosquet N., Appelman B., Ayesha Lavell A.H., Van Vught L.A., Burger J.A., et al. Cross-Reactive Antibodies after Sars-Cov-2 Infection and Vaccination. Elife. 2021;10:e70330. doi: 10.7554/eLife.70330.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.70330</ArticleId><ArticleId IdType="pmc">PMC8610423</ArticleId><ArticleId IdType="pubmed">34812143</ArticleId></ArticleIdList></Reference><Reference><Citation>Song G., He W., Callaghan S., Anzanello F., Huang D., Ricketts J., Torres J.L., Beutler N., Peng L., Vargas S., et al. Cross-Reactive Serum and Memory B-Cell Responses to Spike Protein in SARS-CoV-2 and Endemic Coronavirus Infection. Nat. Commun. 2021;12:2938. doi: 10.1038/s41467-021-23074-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23074-3</ArticleId><ArticleId IdType="pmc">PMC8134462</ArticleId><ArticleId IdType="pubmed">34011939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sealy R.E., Hurwitz J.L. Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2): Mini-Review and a Murine Study. Microorganisms. 2021;9:1643. doi: 10.3390/microorganisms9081643.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9081643</ArticleId><ArticleId IdType="pmc">PMC8398386</ArticleId><ArticleId IdType="pubmed">34442723</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y.L., Hafezi M., Chia A., Chng M.H.Y., Lin M., Tan N., Linster M., et al. SARS-CoV-2-Specific T Cell Immunity in Cases of COVID-19 and SARS, and Uninfected Controls. Nature. 2020;584:457–462. doi: 10.1038/s41586-020-2550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Soto D., Bueno P., Garaigorta U., Gastaminza P., Bueno J.L., Duarte R.F., Jara R., Valés-Gómez M., Reyburn H.T. SARS-CoV-2 Membrane Protein-Specific Antibodies from Critically Ill SARS-CoV-2–Infected Individuals Interact with Fc Receptor–Expressing Cells but Do Not Neutralize the Virus. J. Leukoc. Biol. 2024;115:985–991. doi: 10.1093/jleuko/qiae017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jleuko/qiae017</ArticleId><ArticleId IdType="pubmed">38245016</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>